{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:53:06Z","timestamp":1784119986017,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatic encephalopathy (HE), a morbid ordeal affecting chronic liver disease patients always insists for the search of a rational, superior &amp; infallible agent beyond the time-proven standards i.e., Lactulose &amp; Rifaximin. In this RCT, we compared the efficacy of intravenous (IV) <jats:sc>l<\/jats:sc>-ornithine-<jats:sc>l<\/jats:sc>-aspartate(LOLA) versus Oral LOLA in patients with chronic liver disease(CLD) enduring overt Hepatic Encephalopathy(OHE). 40 CLD patients with OHE were randomly assigned IV or oral LOLA in a 1:1 ratio. Patients were graded for HE and monitored for serum ammonia levels from day 1 to day 5. The aim was to compare IV versus oral LOLA efficacy in HE grades improvement and its correlation with ammonia levels. The study was registered with clinical trials registry-India, CTRI\/2020\/12\/029943. Baseline characteristics of patients in both groups were similar. The mean difference in ammonia levels from day 1 to day 5 was 55.4\u2009\u00b1\u200932.58\u00a0\u00b5mol\/L in the IV LOLA group and 60.75\u2009\u00b1\u200913.82\u00a0\u00b5mol\/L in the oral LOLA group (p\u2009=\u20090.511). Significant reductions in ammonia levels were observed from day 1 to day 5 within each group (p\u2009&lt;\u20090.001). HE grade &amp; ammonia correlated positively in both groups. LOLA, regardless of administration route, has demonstrated efficacy in OHE.<\/jats:p>","DOI":"10.1038\/s41598-024-62293-8","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T23:02:52Z","timestamp":1716591772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intravenous versus oral \u2018l-ornithine-l-aspartate\u2019 in overt hepatic encephalopathy: a randomized comparative study"],"prefix":"10.1038","volume":"14","author":[{"given":"Ashok","family":"Jhajharia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Jana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachis","family":"Ashdhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Nijhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"issue":"1","key":"62293_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11011-019-00463-8","volume":"35","author":"RF Butterworth","year":"2020","unstructured":"Butterworth, R. F. Beneficial effects of l-ornithine l-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: A systematic review with meta-analysis. Metab. Brain Dis. 35(1), 75\u201381 (2020).","journal-title":"Metab. Brain Dis."},{"issue":"3","key":"62293_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jceh.2018.05.004","volume":"8","author":"RF Butterworth","year":"2018","unstructured":"Butterworth, R. F., Kircheis, G., Hilger, N. & McPhail, M. J. W. Efficacy of l-ornithine l-aspartate for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: Systematic review and meta-analysis of randomized controlled trials. J. Clin. Exp. Hepatol. 8(3), 301\u2013313 (2018).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"62293_CR3","doi-asserted-by":"crossref","first-page":"1756283X1774341","DOI":"10.1177\/1756283X17743419","volume":"11","author":"M Ventura-Cots","year":"2017","unstructured":"Ventura-Cots, M. et al. Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. Ther. Adv. Gastroenterol. 11, 1756283X17743419 (2017).","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"5","key":"62293_CR4","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S0168-8278(99)80144-5","volume":"30","author":"J Bustamante","year":"1999","unstructured":"Bustamante, J. et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J. Hepatol. 30(5), 890\u2013895 (1999).","journal-title":"J. Hepatol."},{"issue":"12","key":"62293_CR5","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","volume":"362","author":"NM Bass","year":"2010","unstructured":"Bass, N. M. et al. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 362(12), 1071\u20131081 (2010).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"62293_CR6","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1023\/A:1005556826152","volume":"45","author":"RK Dhiman","year":"2000","unstructured":"Dhiman, R. K. et al. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig. Dis. Sci. 45(8), 1549\u20131552 (2000).","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"62293_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1042\/bj2670281","volume":"267","author":"D Ha\u00fcssinger","year":"1990","unstructured":"Ha\u00fcssinger, D. Nitrogen metabolism in liver: Structural and functional organization and physiological relevance. Biochem. J. 267(2), 281\u2013290 (1990).","journal-title":"Biochem. J."},{"issue":"4","key":"62293_CR8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/gut.47.4.571","volume":"47","author":"CJ Rees","year":"2000","unstructured":"Rees, C. J., Oppong, K., Al Mardini, H., Hudson, M. & Record, C. O. Effect of l-ornithine-l-aspartate on patients with and without TIPS undergoing glutamine challenge: A double blind, placebo-controlled trial. Gut 47(4), 571\u2013574 (2000).","journal-title":"Gut"},{"issue":"6","key":"62293_CR9","first-page":"718","volume":"25","author":"MF Chinese Chen","year":"2005","unstructured":"Chinese Chen, M. F., Lin, R. C., Chen, C. H. & Gao, X. C. Therapeutic effect of l-ornithine l-aspartate on liver cirrhosis complicated by hepatic encephalopathy. Di 1 jun yi da xue xue bao Acad. J. First Med. Coll. PLA 25(6), 718\u2013722 (2005).","journal-title":"Di 1 jun yi da xue xue bao Acad. J. First Med. Coll. PLA"},{"issue":"2","key":"62293_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1023\/A:1020613314572","volume":"13","author":"C Rose","year":"1998","unstructured":"Rose, C. et al. l-ornithine-l-aspartate in experimental portal-systemic encephalopathy: Therapeutic efficacy and mechanism of action. Metab. Brain Dis. 13(2), 147\u2013157 (1998).","journal-title":"Metab. Brain Dis."},{"issue":"3","key":"62293_CR11","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/hep.510300311","volume":"30","author":"C Rose","year":"1999","unstructured":"Rose, C. et al. l-ornithine-l-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology 30(3), 636\u2013640 (1999).","journal-title":"Hepatology"},{"issue":"4","key":"62293_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1023\/A:1021934607762","volume":"17","author":"G Kircheis","year":"2002","unstructured":"Kircheis, G., Wettstein, M., Dahl, S. V. & H\u00e4ussinger, D. Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. Metab. Brain Dis. 17(4), 453\u2013462 (2002).","journal-title":"Metab. Brain Dis."},{"issue":"6","key":"62293_CR13","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/hep.510250609","volume":"25","author":"G Kircheis","year":"1997","unstructured":"Kircheis, G. et al. Therapeutic efficacy of l-ornithine-l-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo-controlled, double-blind study. Hepatology 25(6), 1351\u20131360 (1997).","journal-title":"Hepatology"},{"issue":"1","key":"62293_CR14","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.2337\/dc21-S002","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. 2. classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. Diabetes Care 44(1), S15\u2013S33 (2021).","journal-title":"Diabetes Care"},{"issue":"11","key":"62293_CR15","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1007\/s10620-016-4319-7","volume":"61","author":"G Garcia-Tsao","year":"2016","unstructured":"Garcia-Tsao, G. The child-turcotte classification: From gestalt to sophisticated statistics and back. Dig. Dis. Sci. 61(11), 3102\u20133104 (2016).","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"62293_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.22172","volume":"33","author":"PS Kamath","year":"2001","unstructured":"Kamath, P. S. et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33(2), 464\u2013470 (2001).","journal-title":"Hepatology"},{"issue":"3","key":"62293_CR17","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jhep.2014.05.042","volume":"61","author":"American Association for the Study of Liver Diseases, European Association for the Study of the Liver","year":"2014","unstructured":"American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European association for the study of the liver and the American association for the study of liver diseases. J. Hepatol. 61(3), 642\u2013659 (2014).","journal-title":"J. Hepatol."},{"issue":"2","key":"62293_CR18","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/hep.29410","volume":"67","author":"SS Sidhu","year":"2018","unstructured":"Sidhu, S. S., Sharma, B. C., Goyal, O., Kishore, H. & Kaur, N. l-ornithine l-aspartate in bouts of overt hepatic encephalopathy. Hepatology 67(2), 700\u2013710 (2018).","journal-title":"Hepatology"},{"issue":"11","key":"62293_CR19","first-page":"666","volume":"21","author":"S Abid","year":"2011","unstructured":"Abid, S. et al. Efficacy of l-ornithine-l-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy. J. Coll. Physicians Surg. Pak. 21(11), 666\u2013671 (2011).","journal-title":"J. Coll. Physicians Surg. Pak."},{"issue":"4","key":"62293_CR20","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/j.1478-3231.2010.02213.x","volume":"30","author":"M Schmid","year":"2010","unstructured":"Schmid, M. et al. A double-blind, randomized, placebo-controlled trial of intravenous l-ornithine-l-aspartate on postural control in patients with cirrhosis. Liver Int. 30(4), 574\u2013582 (2010).","journal-title":"Liver Int."},{"issue":"9","key":"62293_CR21","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/hepr.12235","volume":"44","author":"MR Alvares-da-Silva","year":"2014","unstructured":"Alvares-da-Silva, M. R. et al. Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled trial. Hepatol. Res. 44(9), 956\u2013963 (2014).","journal-title":"Hepatol. Res."},{"issue":"4","key":"62293_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4103\/1319-3767.136975","volume":"20","author":"K Sharma","year":"2014","unstructured":"Sharma, K. et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: A randomized controlled trial. Saudi J. Gastroenterol. 20(4), 225\u2013232 (2014).","journal-title":"Saudi J. Gastroenterol."},{"issue":"8","key":"62293_CR23","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/MEG.0b013e32834696f5","volume":"23","author":"VV Mittal","year":"2011","unstructured":"Mittal, V. V., Sharma, B. C., Sharma, P. & Sarin, S. K. A randomized controlled trial comparing lactulose, probiotics, and l-ornithine l-aspartate in treatment of minimal hepatic encephalopathy. Eur. J. Gastroenterol. Hepatol. 23(8), 725\u2013732 (2011).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"5","key":"62293_CR24","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S0168-8278(98)80237-7","volume":"28","author":"S Stauch","year":"1998","unstructured":"Stauch, S. et al. Oral l-ornithine-l-aspartate therapy of chronic hepatic encephalopathy: Results of a placebo-controlled double-blind study. J. Hepatol. 28(5), 856\u2013864 (1998).","journal-title":"J. Hepatol."},{"issue":"1","key":"62293_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/apt.12795","volume":"40","author":"M Bai","year":"2014","unstructured":"Bai, M. et al. Randomized clinical trial: l-ornithine-l-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS. Aliment. Pharmacol. Ther. 40(1), 63\u201371 (2014).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"62293_CR26","first-page":"1044","volume":"5","author":"RF Butterworth","year":"2018","unstructured":"Butterworth, R. F. & Gruengreiff, K. l-ornithine l-aspartate (LOLA) for the treatment of hepatic encephalopathy in cirrhosis: Evidence for novel hepatoprotective mechanisms. J. Liver Clin. Res. 5(1), 1044 (2018).","journal-title":"J. Liver Clin. Res."},{"issue":"4","key":"62293_CR27","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3390\/nu14040748","volume":"14","author":"A Horvath","year":"2022","unstructured":"Horvath, A. et al. Oral intake of l-ornithine-l-aspartate is associated with distinct microbiome and metabolome changes in cirrhosis. Nutrients 14(4), 748 (2022).","journal-title":"Nutrients"},{"key":"62293_CR28","first-page":"604","volume":"4","author":"AM Delcker","year":"2000","unstructured":"Delcker, A. M., Jalan, R., Schumacher, M. & Comes, G. l-ornithine l-aspartate versus placebo in the treatment of hepatic encephalopathy: A meta-analysis of randomised placebo-controlled trials using individual data. Hepatology 4, 604 (2000).","journal-title":"Hepatology"},{"key":"62293_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1440-1746.2008.05582.x","volume":"24","author":"Q Jiang","year":"2009","unstructured":"Jiang, Q., Jiang, X. H., Zheng, M. H. & Chen, Y. P. l-ornithine l-aspartate in the management of hepatic encephalopathy: A meta-analysis. J. Gastroenterol. Hepatol. 24, 9\u201314 (2009).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"62293_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/jgh.12142","volume":"28","author":"M Bai","year":"2013","unstructured":"Bai, M., Yang, Z., Qi, X., Fan, D. & Han, G. l-ornithine l-aspartate for hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials. J. Gastroenterol. Hepatol. 28, 783\u2013792 (2013).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"62293_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40265-018-1024-1","volume":"79","author":"RF Butterworth","year":"2019","unstructured":"Butterworth, R. F. & McPhail, M. J. W. l-ornithine l-aspartate (LOLA) for hepatic encephalopathy in cirrhosis: Results of randomized controlled trials and meta-analyses. Drugs 79(1), 31\u201337 (2019).","journal-title":"Drugs"},{"key":"62293_CR32","doi-asserted-by":"publisher","first-page":"S714","DOI":"10.1016\/S0168-8278(18)31688-X","volume":"68","author":"RF Butterworth","year":"2018","unstructured":"Butterworth, R. F., Hilger, N., Kircheis, G. & McPhail, M. J. W. Efficacy of l-ornithine l-aspartate for minimal hepatic encephalopathy in cirrhosis: A systematic review and meta-analysis of randomized controlled trials. J. Hepatol. 68, S714 (2018).","journal-title":"J. Hepatol."},{"key":"62293_CR33","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.14260\/jemds\/2014\/2594","volume":"3","author":"R Manjunath","year":"2014","unstructured":"Manjunath, R., Nagesh, H. N. & Bharadwaj, V. Clinical correlation between arterial and venous ammonia levels in hepatic encephalopathy in cirrhosis of liver. J. Evolut. Med. Dent. Sci. 3, 5322\u20135333 (2014).","journal-title":"J. Evolut. Med. Dent. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62293-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62293-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62293-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T23:15:46Z","timestamp":1716592546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-62293-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["62293"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-62293-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"assertion":[{"value":"4 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11862"}}